GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C4150 Arachidonoyl amideSummary: CB1 receptor agonist -
B2231 Amitriptyline HClTarget: Trk Receptors|5-HT2 Receptors|Norepinephrine transporter|5-HT TransportersSummary: Serotonin /norepinephrine receptor/5-HT4/5-HT2 inhibitor -
B1349 Tetrahydrozoline HClSummary: Adrenergic receptor agonist -
B7067 SDZ WAG 994Summary: A1 adenosine receptor agonist -
B7065 SCH 442416Summary: adenosine A2A receptor antagonist -
C3909 R-Palmitoyl-(1-methyl) EthanolamideSummary: synthetic analog of palmitoyl ethanolamide (PEA) -
B1348 Salbutamol SulfateSummary: β-2 adrenergic receptor agonist -
B2230 Trazodone HClSummary: 5-HT receptor antagonist -
C3642 LH 21Summary: silent CB1 antagonist -
B2229 Palonosetron HClSummary: 5-HT receptor antagonist
